United Therapeutics (NASDAQ:UTHR) Director Jan Malcolm Sells 50 Shares

United Therapeutics Corporation (NASDAQ:UTHR) Director Jan Malcolm sold 50 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $495.01, for a total value of $24,750.50. Following the completion of the sale, the director directly owned 370 shares of the company’s stock, valued at $183,153.70. The trade was a 11.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jan Malcolm also recently made the following trade(s):

• On Tuesday, December 23rd, Jan Malcolm sold 50 shares of United Therapeutics stock. The stock was sold at an average price of $512.12, for a total value of $25,606.00.
• On Thursday, December 11th, Jan Malcolm sold 50 shares of United Therapeutics stock. The stock was sold at an average price of $482.98, for a total value of $24,149.00.

United Therapeutics Stock Performance

Shares of United Therapeutics stock opened at $502.71 on Wednesday. The stock has a market capitalization of $21.65 billion, a PE ratio of 19.05, a price-to-earnings-growth ratio of 4.71 and a beta of 0.84. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $519.99. The stock has a 50 day moving average price of $481.47 and a two-hundred day moving average price of $398.76.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. During the same period last year, the business earned $6.39 EPS. United Therapeutics’s quarterly revenue was up 6.8% compared to the same quarter last year. Research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of UTHR. Royal Bank of Canada lifted its holdings in United Therapeutics by 99.8% during the first quarter. Royal Bank of Canada now owns 65,789 shares of the biotechnology company’s stock worth $20,281,000 after acquiring an additional 32,867 shares during the period. Advisors Asset Management Inc. raised its stake in shares of United Therapeutics by 40.9% during the 1st quarter. Advisors Asset Management Inc. now owns 3,892 shares of the biotechnology company’s stock worth $1,200,000 after purchasing an additional 1,129 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in shares of United Therapeutics by 249.8% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 7,934 shares of the biotechnology company’s stock worth $2,446,000 after buying an additional 5,666 shares during the last quarter. Nissay Asset Management Corp Japan ADV grew its position in United Therapeutics by 0.8% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 5,235 shares of the biotechnology company’s stock valued at $1,614,000 after buying an additional 43 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new position in United Therapeutics during the first quarter valued at about $867,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of analyst reports. UBS Group lifted their price objective on shares of United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a report on Tuesday. HC Wainwright raised their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Wells Fargo & Company boosted their price objective on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Jefferies Financial Group reissued a “buy” rating and issued a $575.00 price objective on shares of United Therapeutics in a research note on Wednesday, November 19th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $509.50.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.